Research and Markets: Flooded by Generics ENT Disorders Therapeutics Market to Witness Meager Growth

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3be296/ent_disorders_mark) has announced the addition of the "ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance" report to their offering.

“ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance”

GBI Research, the leading business intelligence provider, has released its latest research, ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance, which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market.

The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets. The ENT disorder therapeutics market is flooded with several classes of generic drugs. Generic drugs are medications sold under a generic name that are only legal when the branded counterpart's patent expires or has no patent. They have the same formulation as the branded drugs and are launched to the market as and when the branded drug's patent expires. Generic versions of anti-bacterials including Pfizer's Zithromax (azithromycin), Abbott's Biaxin (clarithromycin), Johnson & Johnson's Levaquin (levofloxacin) and Bayer's Avelox (moxifloxacin) have captured the ENT therapeutics market.

These generic drugs provide stiff competition to branded drugs, leading to an overall reduction in the market price of both branded and generic drugs. They are cost-effective both to patients and insurance companies as they cost on average 16% less than the branded varieties. Developing and under developed nations prefer importing generics.

Companies Mentioned: